MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences Cost of Revenue 2011-2026 | ANIX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Quarterly Cost of Revenue Anixa Biosciences
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 595 K | - | - | 2.84 M | 1.09 M | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.84 M | 595 K | 1.51 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
2.91 B | $ 116.92 | 2.67 % | $ 35.5 B |  USA |
 |
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
15.3 M | $ 1.18 | 0.85 % | $ 6.43 M | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 17.92 | 1.41 % | $ 955 M | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 16.24 | 0.93 % | $ 175 M |  China |
 |
Co-Diagnostics
CODX
|
222 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
14.6 M | $ 1.98 | -0.63 % | $ 8.76 M | USA |
 |
Illumina
ILMN
|
1.51 B | $ 128.0 | 1.23 % | $ 20.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 25.19 | 1.45 % | $ 700 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 274.72 | 2.06 % | $ 22.9 B | USA |
 |
Danaher Corporation
DHR
|
10 B | $ 196.19 | 2.71 % | $ 140 B | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K |  Israel |
 |
Myriad Genetics
MYGN
|
248 M | $ 4.77 | 0.63 % | $ 442 M | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 10.34 | 3.61 % | $ 2.24 B | USA |
 |
Natera
NTRA
|
158 M | $ 210.83 | 0.75 % | $ 20.7 B | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
5 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
3.32 M | - | -16.95 % | $ 1.54 M | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 15.83 | -0.5 % | $ 479 M | USA |
 |
Pacific Biosciences of California
PACB
|
114 M | $ 1.47 | 2.08 % | $ 441 M | USA |
 |
Guardant Health
GH
|
349 M | $ 92.84 | -0.49 % | $ 11.6 B | USA |
 |
PerkinElmer
PKI
|
1.44 B | - | -0.91 % | $ 14.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B |  Niderland |
 |
Psychemedics Corporation
PMD
|
13.7 M | - | -1.84 % | $ 15.3 M | USA |
 |
Personalis
PSNL
|
57.8 M | $ 6.33 | 2.59 % | $ 375 M | USA |
 |
Biomerica
BMRA
|
4.81 M | $ 2.15 | -0.46 % | $ 4.94 M | USA |
 |
Quotient Limited
QTNT
|
20.1 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 106.54 | -0.58 % | $ 8.79 B |  Irlanda |